Long-acting amylin analogue
PRODUCT PROFILE
Cagrilintide
£64.00
Cagrilintide is long-acting amylin analogue. Researchers examine it in relation to satiety signalling and body-weight regulation through the amylin pathway.
Why it is distinct
Targets amylin biology, making it mechanistically distinct from every incretin agonist in the category.
- Evidence stageClinical research
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Cagrilintide is long-acting amylin analogue. Researchers examine it in relation to satiety signalling and body-weight regulation through the amylin pathway.
Research focus+
Researchers study whether it can reduce hunger and support weight-loss research. It remains investigational and is not an authorised medicine.
How the mechanism differs+
Engages amylin-family receptors rather than GLP-1, GIP or glucagon receptors, influencing satiety and meal termination.
Evidence and limitations+
Investigational agent with phase 2 monotherapy data and later-stage study in combination with semaglutide.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can reduce hunger and support weight-loss research. It remains investigational and is not an authorised medicine.
Engages amylin-family receptors rather than GLP-1, GIP or glucagon receptors, influencing satiety and meal termination.
Targets amylin biology, making it mechanistically distinct from every incretin agonist in the category.
Investigational agent with phase 2 monotherapy data and later-stage study in combination with semaglutide.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Established
Tirzepatide
£79.0010 mgBatch file pendingDual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.
UnavailableAsk about availability -
Established
Semaglutide
£69.005 mgBatch file pendingA single-pathway GLP-1 comparator rather than a dual or triple incretin agonist.
UnavailableAsk about availability -
Phase 2 clinical research
MOTS-c
£35.64Batch file pendingMOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.
Available · 30 in stockAdd to basket -
Experimental
Retatrutide + Cagrilintide
£59.995 mg + 5 mg | 10 mg + 10 mgBatch file pendingIt combines triple-receptor agonism with a separate amylin pathway, rather than adding another agent acting through the same…
AvailableAdd to basket This product has multiple variants. The options may be chosen on the product page